Wedbush Reaffirms “Neutral” Rating for Blueprint Medicines (NASDAQ:BPMC)
Blueprint Medicines (NASDAQ:BPMC – Get Free Report)‘s stock had its “neutral” rating reissued by equities researchers at Wedbush in a report issued on Monday, Marketbeat.com reports. They currently have a $129.00 target price on the biotechnology company’s stock, up from their prior target price of $128.00. Wedbush’s price target points to a potential upside of […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report)‘s stock had its “neutral” rating reissued by equities researchers at Wedbush in a report issued on Monday, Marketbeat.com reports. They currently have a $129.00 target price on the biotechnology company’s stock, up from their prior target price of $128.00. Wedbush’s price target points to a potential upside of […]
